Home > Boards > US OTC > Biotechs >

Antibe Therapeutics Inc. (ATBPF)

ATBPF RSS Feed
Add ATBPF Price Alert      Hide Sticky   Hide Intro
Moderator: djmurdock
Search This Board: 
Last Post: 9/17/2019 7:11:43 PM - Followers: 12 - Board type: Free - Posts Today: 0

logo
http://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20July%202019.pdf


http://www.antibethera.com/pipeline/ 









Gastric ulcer incidence of ATB-346 (>=3mm diameter) versus naproxen during two-week treatment period # of Subjects that Developed Ulcers 0 15 30 45 60 ATB-346 Naproxen 11 • A successful Phase 2B double blind GI safety study for ATB-346 was completed in March 2018 in 244 healthy volunteers • Validation of GI safety superiority: ATB-346 exhibited an ulceration rate of 2.5% versus 42.1% for naproxen over the two-week treatment period (p<0.0001) • ATB-346 was safe and well-tolerated Strong Phase 2B GI Safety Data 42.1% 2.5% (n = 118) (n = 126)

 

H2S Platform

HOME / H2S PLATFORM

Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.

Global NSAID sales exceed $11 billion annually, a significant market opportunity that could potentially be disrupted by Antibe’s H2S technology.

Now in Phase 2 human clinical trials, Antibe’s lead drug, ATB-346, targets mild-to-moderate pain and inflammation arising from a wide range of medical conditions. In March 2018, ATB-346 showed unequivocal superiority to naproxen in GI safety (2.5% versus 42.1% ulceration rate) in a Phase 2B double-blind clinical trial (see press release). This human proof-of-concept data replicated the results of our pre-clinical studies, and suggests Antibe has potentially surmounted the main barrier to the non-addictive control of pain and inflammation. If ATB-346 obtains regulatory approval, physicians and consumers will gain a radically safer alternative to today’s NSAIDs and to the multi-dimensional dangers of corticosteroids (used for inflammation) and opiates (used for pain).

Antibe has two other promising drug candidates in its pipeline: ATB-352, a potent pain-killer targeting the urgent global need for a safer, non-addictive analgesic for treating severe pain; and ATB-340, GI-safe derivative of aspirin for chronic prevention of cardiovascular disease and cancer chemoprevention.

Rooted in more than ten years of academic and proprietary research, Antibe’s patent-protected drug development technology enables the linking of an NSAID molecule to a hydrogen sulfide-releasing molecule. Notably, hydrogen sulfide (“H2S”) is endogenously produced and utilized throughout the body, serving as an anti-inflammatory agent and signaling molecule. Combined with an expanding scope of indications for NSAID use, the unique properties of hydrogen sulfide promise substantially improved medicines for pain and inflammation across the spectrum of human illness.

ATB-346
Novel anti-inflammatory drug that releases hydrogen sulfide (“H2S”) • Negligible GI damage: greatly superior to existing NSAIDs • No significant effect on blood pressure, unlike existing NSAIDs • Global IP with market protection to ~2030 - Patents granted in major markets (including US, Europe, Japan, China & Canada) 
ATBPF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ATBPF News: Antibe Therapeutics Reports Q3 2015 Interim Financial and Operating Results and Director Resignation 02/27/2015 09:06:00 PM
ATBPF News: Antibe Therapeutics Provides Update on Its Acute Pain Drug ATB-352 11/25/2014 07:30:00 AM
ATBPF News: Antibe Therapeutics Completes Single Ascending Dose Portion of ATB-346 Phase I Program 10/06/2014 07:30:00 AM
ATBPF News: Antibe Therapeutics Reports on Results of AGM Voting 10/03/2014 07:30:00 AM
ATBPF News: OTC Markets Group Welcomes Antibe Therapeutics to OTCQX® 09/15/2014 07:00:00 AM
PostSubject
#170  Sticky Note New investor presentation as well : djmurdock 07/17/19 12:58:26 AM
#196   3 year weekly chart: Pro-Life 09/17/19 07:11:43 PM
#195   20% inside ownership... commitment is apparent... Pro-Life 09/17/19 10:20:27 AM
#194   There are tons of highly skilled individuals partnering here: Pro-Life 09/17/19 10:18:46 AM
#193   July 2019 presentation for investors looks solid as well: Pro-Life 09/17/19 10:16:18 AM
#192   Seems to be a solid company per filings... Pro-Life 09/17/19 10:14:54 AM
#191   big pop to ATE.v/ ATBPF +.05 to C$.39 Bobwins 08/29/19 02:39:03 PM
#190   Drop due to following https://finance.yahoo.com/news/antibe-therapeutics-provid Amatuer17 08/27/19 10:32:14 AM
#189   Well not wholly the response I expected to NotTheFace1337 08/27/19 10:31:55 AM
#188   I’m guessing a recap of: http://www.antibethera.com/2018/08/29/antibe-provides treedoc 08/26/19 09:00:32 AM
#187   https://web.tmxmoney.com/article.php?newsid=8671532321449129&qm_symbol=ATE treedoc 08/26/19 08:51:47 AM
#186   I asked IR about gaining more US exposure djmurdock 08/25/19 01:56:47 AM
#185   Nice close on huge volume!!! djmurdock 08/23/19 04:07:15 PM
#184   Another great day so far. Time for power hour NotTheFace1337 08/23/19 02:57:45 PM
#183   News release djmurdock 08/23/19 12:15:38 AM
#182   What is NR? Amatuer17 08/23/19 12:12:40 AM
#181   I believe the NR next week will be djmurdock 08/22/19 07:20:15 PM
#180   Do we know if enrollment is complete? The trial Amatuer17 08/22/19 06:04:28 PM
#179   Yeah, sure seems like something is brewing! Supposedly djmurdock 08/22/19 04:52:46 PM
#178   volume in Canada has definitely picked up, several Bobwins 08/22/19 11:24:11 AM
#177   Looking really nice here today! ?? NotTheFace1337 08/22/19 10:53:12 AM
#176   Nice volume today! Could be the start to djmurdock 08/19/19 04:44:34 PM
#175   https://www.businesswire.com/news/home/20190807005720/en/Antibe-Therapeutics-Ann Rorschach0311 08/07/19 04:56:49 PM
#174   The P2a topline results by end of summer Amatuer17 08/07/19 08:20:44 AM
#173   Broke through some 6 month resistance today! Chart djmurdock 08/05/19 04:33:37 PM
#172   Great volume today Rorschach0311 08/01/19 04:09:10 PM
#171   http://www.antibethera.com/2019/06/03/antibe-therapeutics-unveils-lead-indicatio djmurdock 07/17/19 12:59:36 AM
#170   New investor presentation as well : djmurdock 07/17/19 12:58:26 AM
#169   https://www.sedar.com/CheckCode.do djmurdock 07/17/19 12:57:36 AM
#168   Good news on Sedar today! "Antibe expects that djmurdock 07/17/19 12:57:19 AM
#167   Wow! http://www.antibethera.com/2019/06/25/antibe-therapeutics-announces-ceo-let djmurdock 06/25/19 12:43:59 PM
#166   The only reason I can think why this djmurdock 06/14/19 06:46:01 PM
#165   https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-rel treedoc 06/03/19 10:06:33 AM
#164   Speculation but: djmurdock 05/14/19 02:36:47 AM
#163   If he pulls it off, it will be Ultraz2 05/03/19 09:28:42 AM
#162   RDHL sports a 1.8 billion market cap on marcg 04/29/19 08:36:36 AM
#161   1.8 billion market cap is bubkis. marcg 04/29/19 08:33:39 AM
#160   30x is a little much dont ya think? Rorschach0311 04/28/19 07:49:44 PM
#159   Naprosyn without the GI problems is a multi marcg 04/26/19 02:22:12 PM
#158   You think this is movement ? Just wait Stocklionking 04/24/19 03:30:13 PM
#157   Some really good movement here recently. Future is NotTheFace1337 04/23/19 02:34:57 PM
#156   Watched this last night. Great video, proactive investor Rorschach0311 04/18/19 08:34:17 AM
#155   Epic video! djmurdock 04/17/19 10:15:43 PM
#154   This our catalyst rn? Il take a piece NotTheFace1337 04/15/19 12:17:02 PM
#153   https://www.marketwatch.com/press-release/veterinary-surgical-instruments-market NotTheFace1337 04/15/19 12:16:36 PM
#152   Good movement today! NotTheFace1337 04/15/19 12:16:06 PM
#151   https://www.facebook.com/groups/162045277846175/ Stocklionking 03/26/19 08:45:08 PM
#150   https://www.bnnbloomberg.ca/investing/video/robert-mcwhirter-discusses-antibe-th djmurdock 03/18/19 10:19:53 PM
#149   https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14641 djmurdock 03/06/19 10:51:23 PM
#148   This guy agrees! Awesome write up! djmurdock 03/05/19 09:44:45 PM
#147   This guy agrees! Awesome write up! djmurdock 03/05/19 09:44:44 PM
PostSubject